Chemours (NYSE:CC) Stock Price Expected to Rise, Truist Financial Analyst Says

Key Points

• Truist Financial raised Chemours' price target from $18.00 to $21.00, indicating a potential upside of 21.86% from its previous close.
• The company's stock has received a mix of ratings from analysts, with five analysts rating it as a Buy and four as Hold, leading to a consensus rating of "Moderate Buy".
• Chemours reported $0.58 earnings per share, exceeding estimates, with revenue for the quarter reaching $1.62 billion, a 5.0% increase year-over-year.

Chemours (NYSE:CC - Get Free Report) had its price target raised by Truist Financial from $18.00 to $21.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the specialty chemicals company's stock. Truist Financial's target price points to a potential upside of 21.86% from the company's previous close.

A number of other equities analysts also recently commented on the company. Wall Street Zen downgraded Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Mizuho raised their price objective on Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a report on Tuesday, July 15th. Royal Bank Of Canada raised their price objective on Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. Zacks Research upgraded Chemours from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 27th. Finally, Barclays cut their price objective on Chemours from $16.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, May 28th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Chemours has a consensus rating of "Moderate Buy" and an average target price of $17.25.

Chemours Trading Down 0.2%

NYSE CC traded down $0.03 during trading hours on Tuesday, hitting $17.23. 407,652 shares of the company's stock were exchanged, compared to its average volume of 3,515,722. The business's 50 day moving average is $14.24 and its 200-day moving average is $12.75. Chemours has a 12-month low of $9.13 and a 12-month high of $22.38. The firm has a market capitalization of $2.58 billion, a P/E ratio of -6.16 and a beta of 1.61. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68.

Chemours (NYSE:CC - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that Chemours will post 2.03 EPS for the current fiscal year.

Insider Activity at Chemours

In other news, CEO Denise Dignam bought 4,068 shares of the firm's stock in a transaction dated Friday, August 8th. The stock was bought at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer owned 191,546 shares in the company, valued at $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new position in Chemours during the 1st quarter valued at approximately $27,000. UMB Bank n.a. boosted its position in Chemours by 73.9% during the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 948 shares during the period. Farther Finance Advisors LLC boosted its position in Chemours by 170.7% during the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 1,444 shares during the period. MTM Investment Management LLC acquired a new position in Chemours during the 2nd quarter valued at approximately $27,000. Finally, SouthState Corp acquired a new position in Chemours during the 1st quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.26% of the company's stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.